Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Abstract Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit the use of a broad therapeutic arsenal in patients with HCC. Although main HCC onc...

Full description

Bibliographic Details
Main Authors: Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky, Benoit Rousseau
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Hepatocellular carcinoma
Checkpoint inhibitor
Drug combination
Immunology
Tumor microenvironment
Online Access:http://link.springer.com/article/10.1186/s40425-019-0824-5

Internet

http://link.springer.com/article/10.1186/s40425-019-0824-5

Similar Items